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Use of Domperidone to Increase Breast Milk Supply: Are women really dying to breastfeed? 
As outrageous as it may seem, recent reports would have you believe that women are indeed risking 
their lives to breastfeed their infants. The potential for domperidone to prolong the QT interval and 
increase the risk of fatal cardiac arrhythmias among susceptible users has been known for a number of 
years.1 Of particular interest is the concept of susceptibility, as original case reports of fatal cardiac 
arrhythmias involved the administration of high dose intravenous domperidone to cancer patients. 
This led to warnings by the Food and Drug Administration in the United States and its subsequent 
complete withdrawal from the US market, in addition to the withdrawal of the intravenous 
formulation from other markets. The oral form of domperidone, however, has remained available for 
use in many other countries.  
Further evidence supporting the association between the use of domperidone and sudden cardiac death 
emerged through the publication of two case-control studies in 2010.2, 3 These studies led to further 
regulatory warnings and prompted the European Medicines Agency’s (EMA) Pharmacovigilance Risk 
Assessment Committee (PRAC) to recently undertake a review of domperidone-containing medicines, 
the findings of which have recently been made public.4 The committee considered that benefits in 
relation to the symptomatic management of nausea and vomiting outweighed associated risks, but 
recommended that dosing be restricted to a maximum of 30mg daily and that it not be used for longer 
than one week.4 An important caveat of this investigation is that it sought to determine whether the 
benefits of domperidone use outweighed associated risks only for its approved indications. As such, 
the review did not consider any aspects of use among lactating women. 
This raises significant questions regarding the relevance and generalizability of this EMA PRAC 
recommendation. Concerns regarding a lack of generalizability are highlighted in a recent study, 
where an increased risk of sudden cardiac death was only observed amongst those >60 years of age 
(aOR 1.64; 95%CI 1.31, 2.05), and not among those ≤60 years of age (aOR 1.1; 95%CI 0.35-3.47).2 
Furthermore, the risk was significantly increased among males (aOR 2.23; 95%CI 1.59, 3.13), but not 




females (aOR 1.25; 95%CI 0.93, 1.67), of all ages combined.2 The combination of being female and 
aged <60 years could be associated with an ever lower risk.  
Despite its use being ‘off-label’, domperidone remains widely used in clinical practice for women 
experiencing low milk suplly,5 with no reports of significant adverse effects. In contrast, evidence 
from a recent systematic review and meta-analysis demonstrated that domperidone is well tolerated by 
breastfeeding mothers and is associated with modest improvements in breast milk volume (overall 
increase of 75%; 95%CI: 55%- 95%).6 This is important, as breastfeeding is associated with 
significant reductions in infant morbidity and mortality,7,8 as well as providing long-term benefits for 
the mother, with reductions in the incidence of certain cancers.9  
These wide-ranging benefits greatly are thought by many to outweigh what amounts to largely 
theoretical risks associated with the use of domperidone for low milk supply.6 That said, the use of 
domperidone, or any other galactagogue, should never be considered a magic bullet nor as a substitute 
for effective non-pharmacological breastfeeding support and encouragement, but it can be used safely 
and effectively where appropriate.6,10 Precautions and contraindications relating to domperidone use 
in susceptible individuals are already present in the product information. As such, further restrictions 
regarding the use of domperidone for lactation do not appear warranted,10 and risk subjecting 
breastfeeding women to the status of therapeutic orphans.  
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